drug · antibody
itepekimab
Phase 3updated 3mo agoby $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 4 investigational indications.
targets
Interleukin-33
all catalysts(0)
nothing on the calendar yet
Trials studying itepekimab
- phase3A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
- phase3An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps
- phase3A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
- phase3A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
- phase3Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
- phase3Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
- phase2Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD
- phase2A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
News(7)
- Regeneron ends eye disease study due to antibody's safety profileThe discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…biospace · 2d ago
- Regeneron ends eye disease study due to antibody's safety profileThe discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…biospace · 2d ago
- Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’Since stepping in as Sanofi’s CEO in April, Belén Garijo has launched a deep look at the pharma’s pipeline, reassessing assets based on “scientific merit” and potential for long-term value in the q…biospace · 14d ago
- Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce has learned.fiercebiotech · 15d ago
- Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOsSanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.biopharma_dive · 20d ago
- Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chestCalls for Regeneron to step up dealmaking have intensified as the company has established an $18 billion cash pile and suffered clinical trial setbacks.biospace · 21d ago
- Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continuesSanofi's new CEO Belén Garijo opened up for the first time about her strategy to reverse a trend of clinical setbacks, including dumping Regeneron-partnered IL-33 candidate itepekimab.fiercebiotech · 22d ago
Data sources
last refreshed 2m ago
Found something off?
comments(0)
5-min edit window · permanent after that